Business Context and Reporting Period
This Form 8-K is a current report filed by Aeglea BioTherapeutics, Inc. (not Spyre Therapeutics, Inc.) on January 6, 2023, regarding events occurring on January 5, 2023. The company is a Delaware corporation with its principal executive offices in Austin, Texas, and its common stock trades on the Nasdaq Global Market under the symbol AGLE.
Key Financial Metrics
This filing does not report revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on executive compensation and personnel changes.
Material Changes
The primary material change reported is the departure of Leslie Sloan as Chief Operating Officer, effective January 5, 2023. The filing states that Dr. Sloan's departure is not related to any legal, compliance, or other matters involving the Company.
Management Commentary and Compensatory Arrangements
Subject to the execution of a general release of claims, Dr. Sloan is entitled to the following severance benefits under her agreement:
- A severance payment of $435,000, representing twelve months of her annual salary.
- A lump sum bonus payment of $174,000.
- Payment of COBRA premiums for group healthcare coverage for twelve months.
- Acceleration of vesting for outstanding option awards equivalent to twelve months of service beyond the separation date.
The complete text of the Severance Agreement is referenced as Exhibit 10.18 to the Company's 2021 Annual Report on Form 10-K.
Investor Verification Checklist
- Verify the total cash outflow impact of the severance package ($609,000 in direct payments plus COBRA premiums).
- Confirm the number of shares subject to accelerated vesting to assess potential dilution.
- Review the Company's 2021 Form 10-K, Exhibit 10.18, for the full terms of the Severance Agreement.
- Monitor subsequent filings for the appointment of a new Chief Operating Officer.